7 Biotech Investor Relations Mistakes That Hurt Valuations

For pharma, biotech, and life sciences commercial teams, marginal gains compound. The 7 items below distill what's working right now across HCP engagement, market access, patient services, and brand operations — drawn from current industry signal and what high-performing teams are quietly doing differently.

1. 1. Replace one underperforming activity to fund it cleanly

   This is one of the few plays where the cost of inaction shows up in headline numbers within two quarters, not five.

2. 2. Map it to a stakeholder you under-engage today

   Commercial leaders treating this as a quarterly habit rather than an annual exercise are pulling away from peers in share of voice and share of script.

3. 3. Make it survive a compliance review before you fall in love with it

   Done right, this protects the brand from late-cycle access surprises and gives medical affairs a credible seat at the commercial planning table.

4. 4. Define the exit criteria the same week you define the goal

   Pair this with a real-world evidence narrative and the payer conversation gets easier; ignore it and the formulary review gets harder.

5. 5. Treat it as an always-on capability, not a campaign

   When this is wired into the planning cycle (not bolted on), forecast accuracy improves and launch readiness reviews become materially less painful.

6. 6. Wire it into your quarterly business review cadence

   The teams winning here have stopped treating market access and marketing as separate disciplines — they share the same dashboards and the same KPIs.

7. 7. Co-own the metrics with market access from day one

   Brands deploying this consistently report measurable lift in engagement quality, not just volume — the kind that translates to script behavior six to nine months downstream.

Putting It Into Practice

None of the items above are revolutionary on their own. The advantage comes from sequencing, measurement, and the discipline to retire activities that no longer move the business. Start with the two or three items most aligned to your next planning cycle, instrument them properly, and let the data decide what scales.

Related Industry Signal

• A new company rises from the ashes of Purdue Pharma — PharmaVoice
• What’s at stake in Amgen’s showdown with the FDA? — PharmaVoice
• Protein degraders gain speed as Arvinas scores landmark approval — PharmaVoice